Ceftibac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceftibac

Property Description
Active ingredient Ceftazidime
Form Sterile powder for injection
Pharmacological class Third-generation Cephalosporin, β-Lactam antibiotic
Common use Elimination of bacterial pathogens
Origin Synthetic compound

Ceftibac is a prescription-only medicine that functions as a highly specialized antibiotic used to treat bacterial infections. It is a synthetic compound administered via the parenteral route, which defines its critical role in managing serious illnesses caused by susceptible bacteria.


What Type of Medicine is Ceftibac (Ceftazidime)?

Ceftibac is a β-lactam antibiotic belonging to the third-generation cephalosporin class, a group clinically recognized for its reliable effectiveness against various bacterial species.

The active ingredient in Ceftibac is Ceftazidime, a molecule chemically designed as a synthetic compound to be more stable and active against certain difficult-to-treat Gram-negative bacteria compared to older antibiotic generations. This classification places it as a crucial resource when facing serious or complex infections that require a potent, specialized intervention. Pharmacological studies confirm Ceftazidime's broad-spectrum coverage, supporting its use in scenarios where the causative bacteria are not yet definitively identified. Ceftazidime's structure includes a pyridinium group, which contributes to its unique stability against certain bacterial enzymes.


Composition, Pharmaceutical Form, and General Purpose

Ceftibac is typically prepared as a sterile powder for injection, intended for reconstitution with a sterile vehicle, such as water or saline solution, before its administration.

This specialized pharmaceutical form means Ceftibac is a single-ingredient product designed exclusively for parenteral administration (either intravenously or intramuscularly). This method is necessary to ensure the active ingredient, Ceftazidime, rapidly achieves high concentrations in the bloodstream and infected tissues throughout the body. The general purpose of this medicine is to eliminate the root cause of the infection through its powerful bactericidal activity, which involves fatally disrupting the synthesis of the bacterial cell wall, allowing the patient's recovery to commence.

What side effects are possible with Ceftibac?

Possible Side Effects and Safety Information

The safety profile for Ceftibac (Ceftazidime) is documented in official government regulatory labeling, categorizing possible adverse reactions by frequency and the body system affected. This information excludes any non-regulatory interpretations, dosing instructions, or therapeutic use guidance.

Frequency-Classified Adverse Reactions

The officially documented adverse effects are classified by their reported frequency:

  • Common: Reactions reported include eosinophilia, thrombocytosis, diarrhea, transient elevation in hepatic enzymes, and localized reactions such as phlebitis at the intravenous (IV) injection site or pain/inflammation after intramuscular (IM) injection.
  • Uncommon: Reactions include candidiasis, neutropenia, leukopenia, thrombocytopenia, headache, dizziness, and transient elevations of blood urea or creatinine.
  • Incidence Not Known (Postmarketing/Undetermined): This category includes reports of anaphylaxis, hemolytic anemia, severe skin reactions (like Stevens-Johnson syndrome or Toxic Epidermal Necrolysis), and neurological events.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for Serious Adverse Reactions (SARs) across several system-organ classes:

  • Neurological: Seizures, encephalopathy, coma, and other neurological sequelae are explicitly listed, particularly associated with high and prolonged drug concentrations.
  • Gastrointestinal: The risk of severe antibacterial agent-associated colitis, including pseudomembranous colitis, is documented.
  • Hypersensitivity: Severe allergic reactions, including anaphylaxis, are listed constraints. The medicine is formally contraindicated in individuals with a known serious hypersensitivity to Ceftibac, other cephalosporins, or other beta-lactam antibiotics.

Population-Specific Safety Note

Regulatory documents stipulate a required dosage adjustment for individuals with impaired renal function. This constraint is critical because failure to reduce the dose in this population can lead to the high and prolonged serum concentrations linked to neurotoxicity (seizures, coma).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Ceftibac (Ceftazidime) overdose focuses on severe neurological risks and defined emergency response actions.


Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Overdosage may result in seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
Physiological systems affected Central Nervous System (CNS) is primarily affected.
Population-specific overdose notes Overdosage has been reported in patients with renal failure or renal insufficiency.
Emergency-response statements Patients should be subject to careful observation and supportive treatment.
When immediate medical help is required Urgent medical help must be sought if the individual has collapsed, experienced a seizure, has trouble breathing, or is unable to be awakened.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage is associated with severe neurological manifestations, including seizure activity and coma.
  • Management requires careful observation and the provision of supportive treatment.
  • The regulatory profile notes that there is no specific antidote known for Ceftibac overdose.
  • For patients with established renal insufficiency, hemodialysis or peritoneal dialysis may be utilized to aid in the removal of the drug from the body.
  • Immediate emergency services contact is required for life-threatening presentations, such as collapse or an inability to be awakened.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Ceftibac overdose profile through a focus on severe CNS manifestations, explicitly listing symptoms like seizure activity and coma. This documented neurotoxicity mandates that any sign of severe presentation must trigger the immediate contacting of emergency services. Management is defined as supportive and non-antidotal, leveraging dialysis procedures when necessary, particularly given the noted risk in patients with renal impairment.

Therapeutic Uses of Ceftibac

What Ceftibac Treats: Main Uses and Benefits

Ceftibac (Ceftazidime) is a specialized, third-generation cephalosporin antibiotic that is generally reserved for managing serious bacterial infections that are commonly applied in hospital settings. Its core therapeutic use is centered around addressing the underlying bacterial cause to support the resolution of acute symptoms and assist with maintaining functional stability.

The medicine is used to manage conditions characterized by periods of heightened symptoms such as septicemia, severe pneumonia, bacterial meningitis, complicated urinary tract infections, and deep skin or intra-abdominal infections. Ceftibac is considered relevant when supportive symptom management is appropriate in high-risk patients, often applied during phases when symptoms become more noticeable, including in contexts like febrile neutropenia and treating hospital-acquired (nosocomial) infections.

The primary benefit is that this approach may provide supportive assistance in managing temporary physiological imbalance, which contributes to maintaining a sense of stability during difficult episodes. The goal is to provide supportive relief:

“It supports the patient during difficult episodes by easing overall distress.”


Supportive Management: Easing Acute Symptoms

Ceftibac is commonly used to help manage symptoms related to systemic imbalance, particularly persistent high fever, chills, and generalized malaise, assisting with easing the overall symptom load.

Eligibility and Restrictions for Use

The eligibility for Ceftibac, also known as Ceftazidime/Avibactam, is strictly defined by regulatory requirements concerning allergies, organ function, and age.

Contraindicated Populations

Classification Exclusion Criteria (Must Not Use)
Absolute Contraindication Known serious hypersensitivity (allergy) to Ceftazidime, Avibactam, or any cephalosporin or other beta-lactam antibacterial agent.

Restricted and Conditional Use

Population Group Eligibility Status (Regulatory)
Renal Impairment Restricted: Mandatory dose reduction is required for patients with moderately or severely impaired kidney function to avoid neurological issues.
Pediatric Patients Established/Limited: Use is generally approved for specific indications from a minimum age (e.g., typically 3 months or 31 weeks gestational age), but not established for certain young subgroups with severe renal impairment.
Older Adults Conditional: Use is generally allowed, but dose adjustment is often necessary due to the high likelihood of age-related decreased kidney function.
Pregnancy/Lactation Cautionary: Use during pregnancy is recommended only if the benefit clearly justifies the potential risk, as human data are limited. Ceftazidime is excreted in breast milk at low levels.

Official regulatory documents require careful consideration of a patient's kidney function and allergy history to determine safe and appropriate use.

What should I know about interactions with other medicines?

Ceftibac Interactions with other medicines and products

Regulatory agencies document specific interactions for Ceftibac (Ceftazidime) that involve alterations in drug exposure, potential efficacy antagonism, and increased risk of toxicity when co-administered with certain other products. These are categorized based on their functional impact.


Documented Interaction Patterns

Interaction Type Interacting Substance(s) Effect Description (Official Labeling)
Increased Systemic Exposure Probenecid Increases Ceftibac serum concentration by reducing its renal clearance via competition for active tubular secretion.
Pharmacodynamic Antagonism Chloramphenicol Co-administration is shown to be antagonistic to the intended antibacterial effect of Ceftibac.
Increased Toxicity Risk Aminoglycosides Increases the potential for nephrotoxicity (kidney damage) and ototoxicity (ear damage).

Administration and Population Notes

Timing Constraint: Ceftibac and Aminoglycosides must be administered separately and should not be mixed in the same IV solution due to in vitro chemical incompatibility. This constraint is procedural and aims to prevent drug inactivation.

Population Note: The risk of certain Neurological Adverse Reactions is increased in patients with renal impairment. This is related to the diminished clearance of the medicine in this population, resulting in heightened systemic drug levels.

Mechanism of Action

How Ceftibac Works

Ceftibac's core mechanism involves acting as an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building and cross-linking the cell wall's peptidoglycan framework.

This targeted molecular interference halts the construction of the rigid outer layer, which is the initial step in the drug's destructive cascade against the pathogen. The failure to synthesize a complete and functional cell wall structurally compromises the bacterium, immediately disrupting its ability to withstand its own high internal osmotic pressure, forcing water into the cell.

The subsequent cellular lysis (rupture) ensures the rapid and complete destruction of the pathogenic organisms. If Ceftibac is a combination product, a secondary component may neutralize bacterial beta-lactamase enzymes, thereby supporting synergistic potentiation and extending the mechanistic activity against strains that produce those enzymes.

Dosage and Administration Information

Ceftibac, which contains the active ingredient ceftazidime or a related cephalosporin antibiotic, is administered parenterally (non-orally), typically via intravenous (IV) infusion or intramuscular (IM) injection.

General Administration

  • Dosage: The precise dosage and frequency are determined by the severity of the infection, the type of microorganism causing it, the patient's age, and their renal function. Adult IV or IM dosages often range from 500 mg to 2 grams, administered every 8 to 12 hours. For severe, life-threatening infections, or in immunocompromised patients, dosages can be increased up to a maximum of 6 grams per day.
  • IV Infusion: When given intravenously, Ceftibac is typically infused over a period of 20 to 60 minutes, though this may vary based on the specific formulation.
  • Duration of Treatment: Therapy is generally continued for a minimum of 2 days after the signs and symptoms of infection have resolved, but may be significantly longer for certain severe or persistent infections such as bone or joint infections.

Renal Impairment

Since ceftazidime is primarily excreted by the kidneys, patients with impaired renal function (Creatinine Clearance <50 mL/min) will require a dosage reduction to prevent accumulation and potential central nervous system (CNS) toxicity, such as seizures or encephalopathy. A healthcare professional must calculate the adjusted dose based on a patient's estimated creatinine clearance or serum creatinine levels. Patients undergoing hemodialysis or peritoneal dialysis will also require specific dosage regimens related to their dialysis schedule.

Important Considerations

  • Completion of Course: It is crucial to complete the entire prescribed course of treatment, even if symptoms improve quickly. Stopping early may lead to a relapse of the infection and can contribute to the development of antibiotic-resistant bacteria.
  • Monitoring: Patients should be monitored for signs of allergic reactions, gastrointestinal issues like C. difficile-associated diarrhea, and neurological symptoms, especially if they have pre-existing renal dysfunction.

Recent Clinical Evidence

Ceftibac: Recent Clinical Evidence

The clinical profile of Ceftibac (an investigational anti-infective compound) has primarily been evaluated through controlled trials focusing on its use against Gram-negative bacterial pathogens, particularly those resistant to established therapies. Research aims to characterize the compound's safety profile, efficacy against specific infections, and pharmacological behavior in human subjects.


Efficacy and Study Design

Recent phase 2 and phase 3 studies have investigated whether Ceftibac is associated with positive clinical outcomes in hospitalized adult patients with complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia (HABP). The trials were designed as randomized, multicenter studies comparing Ceftibac against a control group receiving an active comparator (standard-of-care antibiotic).

Key endpoints across these studies included:

  • Clinical Cure Rate: Assessment of whether patients achieved resolution of signs and symptoms of infection.
  • Microbiological Eradication: Determination of the clearance of the causative bacterial pathogen from the infection site.

Safety and Tolerability

Safety data collected from clinical trials indicated that Ceftibac was generally tolerated across the study populations. Adverse events observed were typically mild to moderate in severity. The most frequently reported adverse events included gastrointestinal disturbances (such as nausea and diarrhea) and mild, transient changes in liver enzyme levels.

Studies also examined the development of drug-resistant organisms following Ceftibac exposure. Monitoring of susceptibility changes in pathogens during and after treatment remains a critical component of ongoing research.

Frequently Asked Questions (FAQ)

Common questions about Ceftibac (FAQ)


Q: How quickly does Ceftibac start working?

According to official product information, Ceftibac's mechanism of action is designed for rapid impact, working immediately to destroy the bacterial cell wall. While the destructive process begins right away, regulatory documents do not provide a specific timeframe for when a patient should expect to observe signs of clinical improvement.


Q: How long after I start taking Ceftibac should I expect to feel better?

Regulatory documents outline the required duration of treatment, which is typically continued for at least two days after the signs and symptoms of the infection have fully resolved. Official sources focus on the duration of the prescribed course and do not make specific promises about the exact moment a person will begin to feel better.


Q: I heard Ceftibac can cause stomach upset. Is this a frequent problem?

Gastrointestinal issues are a known occurrence with Ceftibac. Official safety labeling classifies adverse events like diarrhea and nausea as common, meaning they are among the most frequently reported adverse reactions observed in clinical studies.


Q: What kind of food or drinks should be avoided while taking Ceftibac?

Ceftibac is administered by injection (intravenously or intramuscularly) and is typically administered independently of food consumption. Due to the route of administration, specific food or drink restrictions are not documented in the regulatory labeling.


Q: Is it safe to drink alcohol while I am using Ceftibac?

Official regulatory documents, including sections detailing known drug interactions and restrictions, do not list a specific interaction or contraindication concerning the consumption of alcohol in the product's official information.


Q: What happens if the infection doesn't seem to get better while on Ceftibac?

Official guidance indicates that if a lack of clinical improvement is observed, the patient’s condition may warrant re-evaluation by a healthcare professional. This process may include further testing to confirm the cause of the infection and adjust the treatment plan.


Q: Does Ceftibac affect the gut flora or 'good bacteria'?

Safety documents indicate that, like many antibacterial agents, Ceftibac can disrupt the natural balance of micro-organisms (gut flora) in the body. This is evidenced by the officially documented potential for serious adverse reactions such as C. difficile-associated colitis and candidiasis (a type of yeast infection).


Q: I have heard about something called 'antibiotic resistance.' Is Ceftibac affected by this?

Regulatory agencies emphasize that Ceftibac should only be used to treat infections known or strongly suspected to be caused by susceptible bacteria. This strict usage is critical because the misuse of any antibiotic can contribute to the development of antibiotic-resistant bacteria.


Q: How is Ceftibac different from similar antibiotics I've heard of?

Ceftibac is classified as a third-generation cephalosporin, which is a type of beta-lactam antibiotic. This classification is relevant to its intended use and distinguishes it by its activity profile, particularly its documented efficacy against certain Gram-negative bacteria.


Q: Why are there different strengths or forms of Ceftibac available?

Ceftibac is supplied as a sterile powder for injection in varying strengths (e.g., 500 mg, 1 g, 2 g). Regulatory labeling requires these different strengths to provide healthcare professionals with options for administration based on factors like the patient's infection, body weight, and kidney function.


Q: Does Ceftibac have any impact on mental clarity or mood?

Official safety data lists adverse reactions that affect the nervous system, including headache and dizziness. Regulatory documents also note the potential for more serious neurological events like seizures and encephalopathy, particularly in patients with impaired kidney function.


Q: What is the half-life of Ceftibac, or how long does it stay in the body?

Pharmacokinetic studies, documented in official regulatory labeling, show that the half-life of Ceftibac (ceftazidime) is approximately two hours in individuals with normal kidney function. The half-life describes the time required for half of the medicine to be eliminated from the bloodstream.


Q: Is Ceftibac available over-the-counter in any country?

Across the regions where it is officially approved and labeled for use, Ceftibac is classified as a prescription-only medicine. It is not available for purchase over the counter.


Q: Can I take Ceftibac for a common cold or flu?

Ceftibac is an antibacterial medicine indicated for the treatment of specific infections caused by susceptible bacteria. Regulatory documents state it is not effective against, and is not indicated for, the treatment of viral illnesses such as the common cold or flu.


Q: Are there any warnings about driving or operating machinery while taking Ceftibac?

Official safety documents list adverse reactions such as dizziness and headache that are known to potentially affect alertness. While regulatory labeling does not contain a specific restriction on driving, the potential for such neurological side effects is acknowledged.

How should Ceftibac be stored and disposed of?

Storage and Disposal Requirements for Ceftibac (Ceftazidime)

The dry powder for injection must be stored in its original outer carton and kept at a temperature not exceeding 25 C to protect it from light. The medicine must be kept out of the sight and reach of children.


Stability of Prepared Solutions

Once reconstituted, the solution's stability is limited. The solution is typically stable for up to 24 hours when refrigerated (2 C to 8 C). Vials are for single use only.


Disposal Instructions

Any unused product or waste material must be disposed of in accordance with local requirements. It should not be disposed of via household wastewater or standard household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ceftibac found in:

A-Z Index: